Abstract: Provided is an oncolytic virus expressing interferon. Specifically provided is an oncolytic adenovirus comprising a fusion protein expressing interferon, said oncolytic virus being capable of effectively suppressing tumors in vitro and in vivo.

Abstract: Provided is an oncolytic virus expressing a PD-1 binding protein, i.e., an oncolytic adenovirus comprising a fusion protein expressing a PD-1 single-chain antibody, wherein the fusion protein has a structure of S-VL-L-VH-Fc, S is an optional signal peptide sequence, VL is the light chain variable region of the PD-1 single-chain antibody, L is a flexible linker, VH is the heavy chain variable region of the PD-1 single-chain antibody and Fc is an immunoglobulin Fc fragment.

Abstract: Provided is an oncolytic virus expressing interferon. Specifically provided is an oncolytic adenovirus comprising a fusion protein expressing interferon, said oncolytic virus being capable of effectively suppressing tumors in vitro and in vivo.

Abstract: Provided is an oncolytic virus expressing a PD-1 binding protein, i.e., an oncolytic adenovirus comprising a fusion protein expressing a PD-1 single-chain antibody.

Abstract: This present invention disclosed a tumor-targeting gene-virus ZD55-IL-24, which is a recombinant Ad5 with a deletion of E1B 55K da gene and carries the anti-tumor gene IL-24. This present invention also disclosed its construction method and its application in cancer gene-therapy. The tumor-targeting gene-virus ZD55-IL-24 of this invention can be used in the therapy of many kinds of tumors, so it can be used in developing the new effective tumor therapy medicine.

Abstract: The present invention disclosed a kind of gutless adenovirus vector and the construction method thereof. Two structural independent but functional related cassettes, the trans-activator (TA) and anti-tumor cassette, are both carried by the gutless vector. hTERT promoter restricts the expression of TA only in tumor cells, and RU486, associated with TA, regulates the expression of interesting gene: when needed, add the RU486 and the gene expression is on, and when not needed, remove the RU486 and the gene expression is off. Tumor-specificity and small molecule regulation of the vector spare the toxicity to the normal tissue caused by the foreign gene product and endow the gene's long lifetime expression in vivo. The vector of the present invention shows many advantages over traditional adenovirus vectors in targeting, gene regulation and expression lifetime.